Traws Pharma
TRAW
34 hedge funds and large institutions have $10.1M invested in Traws Pharma in 2021 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 6 closing their positions.
150% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 6
36% more funds holding
Funds holding: 25 → 34 (+9)
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
0.12% more ownership
Funds ownership: 0.41% → 0.53% (+0.12%)
9% less capital invested
Capital invested by funds: $11.1M → $10.1M (-$1M)
45% less call options, than puts
Call options by funds: $204K | Put options by funds: $368K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Alyeska Investment Group
Chicago,
Illinois
|
+$1.29M |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$1.24M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$924K |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$854K |
| 5 |
PVI
Pura Vida Investments
New York
|
+$773K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$333K |
| 2 |
Morgan Stanley
New York
|
-$312K |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$248K |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$169K |
| 5 |
Voloridge Investment Management
Jupiter,
Florida
|
-$140K |
TRAW Hedge Fund Activity: Q3 2021 in Review
34 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q3 2021, worth a combined $10.1M — down 9.1% from $11.1M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new TRAW positions and 6 closed out — a net gain of 9 holders — while 8 added to existing stakes and 7 trimmed.
The largest buyer was Alyeska Investment Group, opening a new position worth an estimated $1.29M. The largest seller was State Street, cutting an estimated $333K.
- 34 institutional investors held Traws Pharma (TRAW) as of Q3 2021, up from 25 in Q2 2021.
- Funds reported $10.1M of Traws Pharma stock for Q3 2021, down 9.1% quarter-over-quarter.
- 15 funds opened new Traws Pharma positions in Q3 2021 and 6 closed out, a net change of +9 holders.
- The largest Traws Pharma buyer in Q3 2021 was Alyeska Investment Group, an estimated $1.29M added.
- The largest Traws Pharma seller in Q3 2021 was State Street, an estimated $333K sold.
Based on aggregated 13F filings for Q3 2021.